Nov 02, 2023
Immutep Announces New Biomarker Data from TACTI-002 Phase II in First Line Non-Small Cell Lung Cancer
Nov 01, 2023
Immutep to Participate in November Investor Events
Oct 30, 2023
Immutep Quarterly Activities Report Q1 FY24
Oct 25, 2023
Immutep Receives ~A$1.13 Million R&D Tax Incentive
Oct 24, 2023
Immutep Reports Promising Clinical Data from INSIGHT-003 Trial at ESMO Congress 2023
